<?xml version="1.0" encoding="UTF-8"?>
<p>Efavirenz, which is recommended by the World Health Organization (WHO) for HIV/AIDS treatment, has been named one of the best components for first and second line therapy. The price from Merck was $468 per patient per year, which was more than double the price of Indian generics. With Merckâ€™s original price, the Thai Ministry of Health (MOH) was only able to cover two-thirds of the population in need. After failed negotiations with Merck [
 <xref ref-type="bibr" rid="CR18">18</xref>, 
 <xref ref-type="bibr" rid="CR19">19</xref>], the Thai government issued a compulsory license for efavirenz on December 6, 2006, and began the local production with the government pharmaceutical organization (GPO). The price of the drug dropped about 50% from $67 to $38.5 per month [
 <xref ref-type="bibr" rid="CR20">20</xref>]. This was the first time Thailand used a strategy permitted under both patent law and the Protocol Amending the TRIPS Agreement.
</p>
